Why do things keep getting pushed back with sibeprenlimab? According to the presentation given last month at the BLA is supposed to be submitted early this year, so the launch should be Q4, not Q1 or Q2 next year. They had the data as of October last year...but they have not given ANY specifics about the data- only that it met the primary endpoint. With every other IgAN drug the proteinuria decrease was shared right away. This seems sketchy.
